DeepMed Research

AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Metastatic Adult Soft Tissue Sarcoma
Recurrent Adult Soft Tissue Sarcoma

Interventions: Drug: Doxorubicin
Biological: Durvalumab and Tremelimumab

First Posted Date: 2017-10-23

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 103

Registration Number: NCT03317457

Locations: 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany

Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy

Phase 1

Completed

Conditions: Pretreated Metastatic Colorectal Cancer

Interventions: Drug: TAS 102
Drug: Regorafenib

First Posted Date: 2017-10-10

Last Posted Date: 2021-03-26

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 12

Registration Number: NCT03305913

Locations: 🇩🇪
Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Mainz, Germany

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Phase 2

Conditions: Advanced Cancer
Metastatic Cancer
Transitional Cell Carcinoma

Interventions: Biological: Nivolumab/Ipilimumab

First Posted Date: 2017-07-18

Last Posted Date: 2021-11-03

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 169

Registration Number: NCT03219775

Locations: 🇦🇹
Univ. Klinik für Innere Medizin, Graz, Austria
🇦🇹
Ordensklinikum Linz - KH Barmherzige Schwestern, Linz, Austria
🇦🇹
Universitätsklinikum Salzburg, Salzburg, Austria

and more 24 locations

Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-06-23

Last Posted Date: 2025-04-04

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 30

Registration Number: NCT03197467

Locations: 🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany

Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers

Phase 2

Terminated

Conditions: Cancer of Head and Neck

Interventions: Drug: Pembrolizumab Injection
Drug: Methotrexate Injectable Solution

First Posted Date: 2017-06-21

Last Posted Date: 2023-02-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 47

Registration Number: NCT03193931

Locations: 🇩🇪
Medizinsche Hochschule Hannover, Hannover, Germany

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Avelumab

First Posted Date: 2017-06-02

Last Posted Date: 2022-09-29

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 43

Registration Number: NCT03174405

Locations: 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Phase 2

Active, not recruiting

Conditions: Adenocarcinoma Metastatic
Biliary Tract Cancer
Adenocarcinoma of the Biliary Tract
Adenocarinoma Locally Advanced
Non-Resectable Hepatocellular Carcinoma
Intrahepatic Bile Duct Carcinoma
Extrahepatic Bile Duct Carcinoma

Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A)
Drug: Arm Cisplatin + Gemcitabine (Arm B)

First Posted Date: 2017-02-07

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 93

Registration Number: NCT03044587

Locations: 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany

Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

Phase 2

Completed

Conditions: Lung Adenocarcinoma Metastatic
Metastatic Lung Cancer
Nonsmall Cell Lung Cancer
Large Cell Lung Carcinoma Metastatic
Carcinoma，Non-Small-Cell Lung

Interventions: Drug: Radiotherapy
Drug: Nivolumab

First Posted Date: 2017-02-07

Last Posted Date: 2021-01-13

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 101

Registration Number: NCT03044626

Locations: 🇩🇪
DRK Kliniken Berlin Mitte, Berlin, Germany
🇩🇪
Evangelische Lungenklinik Berlin, Berlin, Germany
🇩🇪
Krankenhaus Nordwest, Frankfurt / Main, Germany

and more 13 locations

Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies

Phase 2

Completed

Conditions: Cholangiocarcinoma Non-resectable
Cholangiocarcinoma Metastatic
Cholangiocarcinoma of the Gallbladder
Cholangiocarcinoma Advanced

Interventions: Drug: nal-IRI
Drug: 5-FU
Drug: leucovorin

First Posted Date: 2017-02-06

Last Posted Date: 2022-05-18

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 100

Registration Number: NCT03043547

Locations: 🇩🇪
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer
Rectosigmoid Cancer

Interventions: Drug: Oxaliplatin
Drug: 5-FU
Drug: Leucovorin
Biological: Aflibercept

First Posted Date: 2017-02-06

Last Posted Date: 2023-02-06

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 119

Registration Number: NCT03043729

Locations: 🇩🇪
Tagestherapiezentrum am ITM & III. Med. Klinik, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy